Skip to main content
Equibles
JUNS logo

JUNS · Jupiter Neurosciences, Inc. · Metrics

Track JUNS — free

Use JUNS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research JUNS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.58 -0.20 (-7.19%) At close · Oct 22
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Our management has concluded that our historical recurring losses from operations and negative cash flows from operations as well as our dependence on private equity and other financings raise substantial doubt about our ability to continue as a going concern and our auditor has included an explanatory paragraph relating to our ability to continue as a going concern in its audit report for the fiscal years ended December 31, 2025 and 2024.”
View the 10-Q filed Aug 14, 2026
Market Cap
$2.14M
Shares
770,081
Volume · Oct 22 10.15K Avg daily vol (54 sessions) 1.06M

JUNS metrics

45 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$2.58
Market cap
$2.14M

Price action

20 metrics
Price change (1W)
-17.8%
Price change (30D)
-13.1%
Price change (3M)
—
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
—
Annualized volatility (3M)
—
Beta
—
RSI (14D)
40.0
Price vs SMA 50
-26.0%
Price vs SMA 200
—
Avg volume (3M)
1.06M
Relative volume
0.0
Average dollar volume
$6.37M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
770,081

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
52.9×
reciprocal yield 1.9%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-429.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
80.6%
Operating margin
-40,873.2%
Trailing 12 months
Net margin
-39,662.8%
Gross profit (TTM)
—
Operating profit (TTM)
−$9.81M
Net income (TTM)
−$9.20M
Trailing 12 months
Diluted EPS (TTM)
$-18.49
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-3.99

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
$40,448
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+26.0%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-247.4%
Debt / equity
—
Current ratio
0.7
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
0.6
Interest coverage
-36.0
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
—
Total assets
$3.72M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$7.25M
Capital expenditures (TTM)
—
R&D (TTM)
$1.87M
SG&A (TTM)
—
Stock compensation (TTM)
$2.53M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
13
13F filer change QoQ
+3
Institutional ownership
2.2%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
2.3%
Private-fund adviser ownership
0.0%
Active holders' share change QoQ
-29.5%
Holder tenure
1.8
Price vs estimated holder cost
-54.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.5%

Short interest

3 metrics
Short interest
4.6%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
46 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1679628 CUSIP 48208B302 Visit website Investor relations